For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Adalimumab - Psoriatic arthritis
PAD Profile : Adalimumab - Psoriatic arthritis
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Ciclosporin
- Etanercept
- Golimumab
- Infliximab
- Sulfasalazine
- Ustekinumab (Psoriasis)
- Certolizumab pegol
- Apremilast
- Secukinumab
- Ixekizumab
- Tofacitinib
- Methotrexate
- Guselkumab (Psoriasis)
- Upadacitinib
- Risankizumab
Other Indications
- Ankylosing spondylitis
- Inflammatory bowel disease
- Psoriasis
- Psoriasis (Hand and foot)
- Rheumatoid arthritis
- Non-radiographic axial spondyloarthritis
- Localised Psoriasis
- Behcet's syndrome
- Non-infectious uveitis
Additional Documents
Committee Recommendations
The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed the reviewed and updated Psoriatic arthritis high cost immunomodulator treatment pathway.
The Surrey Heartlands ICS Area Prescribing Committee have agreed an update of the Psoriatic Arthritis High Cost immunomodulator Drug Treatment Pathway.
The pathway has been updated following guidance from the Regional Medicines Optimisation Committee in May 2020, in relation to the sequential use of biologic medicines.
The Medicines and Healthcare Products Regulatory Agency (MHRA) recommends to prescribe biological products by brand name to ensure that substitution of a biosimilar product does not occur when the medicine is dispensed by the pharmacist. Https://www/gov/uk/drug-safety-update/biosimilar-products
Primary care prescriber should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.